Prof. Dr. Johann Bauersachs
Direktor der Klinik für Kardiologie und Angiologie
- 1993
Promotion (magna cum laude) - 1993 – 1995
Arzt im Praktikum, Medizinische Klinik IV, Universitätsklinikum Frankfurt - 1995
Approbation als Arzt - 1995 – 1996
Wiss. Assistent, Zentrum der Physiologie, Universitätsklinikum Frankfurt - 1996 – 1999
Assistenzarzt, II. Medizinische Klinik, Universitätsklinikum Mannheim - 1999 – 2003
Assistenzarzt, Medizinische Klinik, Universitätsklinikum Würzburg - 1999 – 2004
Wissenschaftlicher Sekretär SFB 355 - 2000
Facharzt für Innere Medizin - 2002
Schwerpunktbezeichnung Kardiologie - 2003 – 2010
Oberarzt Medizinische Klinik I – Kardiologie, Universitätsklinikum Würzburg - 2006 – 2010
Wissenschaftlicher Sekretär SFB 688 - 2001
Habilitation für das Fach Innere Medizin, Erteilung der Venia legendi und Ernennung zum Privatdozenten - 2008 – 2010
Leitender Oberarzt, Medizinische Klinik I, Universitätsklinikum Würzburg - 2008
Ernennung zum apl. Professor - 2008
Zusatzbezeichnung „Internistische Intensivmedizin“ - 2010
Ruf auf die W3-Professur Kardiologie/Angiologie Universität Gießen - ab 2010
W3-Professur und Direktor der Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover - ab 2014
DGK-Zertifikat „Zusatzqualifikation Interventionelle Kardiologie“ - ab 2018
DGK-Zertifikat „Zusatzqualifikation Herzinsuffizienz“ - ab 2021
DGK-Zertifikat „Zusatzqualifikation Kardiovaskuläre Intensiv- und Notfallmedizin
- 2001
Oskar-Lapp-Preis der Deutschen Gesellschaft für Kardiologie - 2004
Albert-Fraenkel-Preis der Deutschen Gesellschaft für Kardiologie - 2006
Parmley-Preis des American College of Cardiology - 2012
Bernard and Joan Marshall Distinguished Investigator Award, British Society for Cardiovascular Research - 2016
Ernennung zum Ehrenmitglied der „Koreanischen Gesellschaft für Kardiologie“ - 2018
Paul Morawitz Preis der Deutschen Gesellschaft für Kardiologie - 2019
Ernennung zum Ehrenmitglied der „Romanian Society of Cardiology“ - 2021
Silberne Ehrennadel der Deutschen Gesellschaft für Kardiologie - 2022
ScholarGPS Highly Ranked Scholar - 2023
Highly cited reasearcher inClinical Medicine (Clarivate)
- PCT/EP2007/008772: microRNA (miRNA) for the diagnosis and treatment of heart diseases
- PCT/EP2009/051986: MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
Akutes Koronarsyndrom, Linksventrikuläre Heilung und Remodelling, Akute und chronische Herzinsuffizienz, Intensivmedizin. Pathophysiologie und Behandlung der peripartalen Cardiomyopathie; Aldosteron-/Mineralocorticoidrezeptor bedingte Mechanismen, nicht-kodierende RNAs
Kennzahlen
Publikationen 1.133
H-Index (Web of Science) 106
H-Index (Google Scholar) 134
- Sprecher der Klinischen Forschergruppe (KFO) 311 (www.kfo311.de/)
“(Prä-)terminales Herz und Lungenversagen- Entlastung und Reparatur”, Medical School Hannover; gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Mitglied Fachkollegium Medizin der Deutschen Forschungsgemeinschaft, 2012-2020
Sprecher 2016-2020 - American Heart Association, Fellow
- European Society of Cardiology, Fellow
Heart Failure Association (HFA) der ESC, Fellow
HFA Study Group Peripartum Cardiomyopathy, Vorsitzender
HFA Board Member 2013-2020, Vorsitzender Klinische Sektion der HFA 2018-2020
Member of the ESC Programme Committee 2014-2018, and 2020-2022
Member of the ESC Communication Committee 2020-2022
Vorsitzender der ESC Working Group „Myocardial Function“ 2012-2014
Member of the ESC Guidelines Task Forces „Management of cardiovascular diseases during pregnancy 2018“, and „Management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation 2020“ Deutsche Gesellschaft für Kardiologie (DGK), Vorstandsmitglied 2017-23
Mitglied der Kommission Klinische Kardiovaskuläre Medizin 2017-21, Vorsitz 2019-21
Kongresspräsident “DGK Herztage 2018”
Mitglied der DGK Programmkommission 2013-2018- ESAC Deutschland e. V. – Verein zur Förderung der Aldosteronforschung; Vorsitzender
- DIGIT-HF Studie: “DIGitalis to Improve ouTcomes in patients with advanced chronic Heart Failure”
(http://digit-hf.de/); gefördert vomBundesministerium für Bildung und Forschung: Studienleiter - Cardior Pharmaceuticals (www.cardior.de/): Mitglied des Advisory Boards 2017- 2021
- Heartbeat.bio (https://heartbeat.bio/): Member Scientific Advisory Board
- Co-Editor:
ESC Textbook of Heart Failure, OUP 2023 - Deputy Editor:
European Heart Journal - Associate Editor:
Cardiovascular Research - Editorial Board Mitglied:
Basic Research in Cardiology, Clinical Research in Cardiology, ESC Heart Failure, Herz – Cardiovascular Diseases
Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, INSERM und ANR-Frankreich, Circulation, Circulation Research, Hypertension, JACC, European Heart Journal, European Journal of Heart Failure, Thrombosis Haemostasis und andere.
van der Meer P, van Essen B, Viljoen C, Böhm M, Jackson A, Hilfiker-Kleiner D, Hoevelmann J, Mebazaa A, Farhan HA, Goland S, Ouwerkerk W, Petrie MC, Seferović PM, Tromp J, Sliwa K, Bauersachs J. Bromocriptine treatment and outcome in patients with peripartum cardiomyopathy: the EORP PPCM registry. Eur Heart J 2024 Sep 2:ehae559. doi: 10.1093/eurheartj/ehae559
Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, Batkai S, Viereck J, Rump S, Filippatos G, Granzer U, Ponikowski P, de Boer RA, Vardeny O, Hauke W, Thum T. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. Eur J Heart Fail 2024; doi: 10.1002/ejhf.3139.
Packer M, Cleland JGF, Bauersachs J. Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. Eur Heart J. 2024:ehae300. doi: 10.1093/eurheartj/ehae300.
Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, Batkai S, Viereck J, Rump S, Filippatos G, Granzer U, Ponikowski P, de Boer RA, Vardeny O, Hauke W, Thum T. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. Eur J Heart Fail 2024; doi: 10.1002/ejhf.3139.
Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, …, Bhatt DL, Hernandez AF. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455-1466. doi: 10.1056/NEJMoa2314051.
von Haehling S, Assmus B, Bekfani T, Dworatzek E, Edelmann F, Hashemi D, Hellenkamp K, Kempf T, Raake P, Schütt KA, Wachter R, Schulze PC, Hasenfuss G, Böhm M, Bauersachs J. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clin Res Cardiol. 2024. doi: 10.1007/s00392-024-02396-4.
Fraccarollo D, Geffers R, Galuppo P, Bauersachs J. Mineralocorticoid receptor promotes cardiac macrophage inflammaging. Basic Res Cardiol. 2024;119(2):243-260. doi: 10.1007/s00395-024-01032-6
Jackson AM, Goland S, Farhan HA,…, Böhm M, Jhund PS, Maggioni AP, van der Meer P, Sliwa K, Bauersachs J, Petrie MC. A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry. Eur Heart J. 2024:ehad888. doi: 10.1093/eurheartj/ehad888.
Bauersachs J, de Boer RA, Zieroth S. The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies. Eur Heart J 2024; doi: 10.1093/eurheartj/ehad878.
Sliwa K, van der Meer P, Viljoen C, …, Seferovic P, Böhm M, Pieske B, Johnson MR, Bauersachs J; EURObservational Research Programme. Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: A study of the ESC EORP PPCM registry. Int J Cardiol. 2024;398:131596. doi: 10.1016/j.ijcard.2023.131596.
Bauersachs J, Soltani S. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango. Eur Heart J 2023; doi: 10.1093/eurheartj/ehad540
*Jackson AM, *Bauersachs J, Petrie MC, van der Meer P, …., Maggioni AP, Briton O, Sliwa K; EurObservational Research Programme in conjunction with the HFA of the ESC Study Group on Peripartum Cardiomyopathy. Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM Registry. Eur J Heart Fail 2023; doi: 10.1002/ejhf.3055
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Filippatos G, Gustafsson F, Lam CSP, Lund LH, Mentz RJ, Pieske B, Ponikowski P, Senni M, Skopicki N, Voors AA, Zannad F, Zieroth S, Butler J. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3. J Am Coll Cardiol. 2023;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057.
Diekmann J, Neuser J, Röhrich M, Derlin T, Zwadlo C, Koenig T, Weiberg D, Jäckle F, Kempf T, Ross TL, Tillmanns J, Thackeray JT, Widder J, Haberkorn U, Bauersachs J, Bengel FM. Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study. J Nucl Med. 2023;64(8):1279-1286. doi: 10.2967/jnumed.122.265147.
Mullens W, Schulze PC, Westphal J, Bogoviku J, Bauersachs J. Great Debate: In patients with decompensated heart failure Acetazolamide in addition to loop diuretics is the first choice. Eur Heart J. 2023;44(24):2159-2169. doi: 10.1093/eurheartj/ehad266.
Bavendiek U, Großhennig A, …, Störk S, Koch A, Bauersachs J. Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial. Clin Res Cardiol 2023; doi: 10.1007/s00392-023-02199-z.
van Veldhuisen D, Bauersachs J. Digitalis in Heart Failure: declining use and ongoing outcome trials. Eur Heart J 2023, doi: 10.1093/eurheartj/ehad185
Bauersachs J, Olsson KM. Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development? Eur Heart J. 2022 Aug 1:ehac387. doi: 10.1093/eurheartj/ehac387.
Bauersachs J, Koenig T. Peripartum cardiomyopathy – a global challenge. Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2636.
Frantz S, Hundertmark M, Schulz-Menger J, Bengel F, Bauersachs J. Left ventricular remodelling post myocardial infarction: pathophysiology, imaging and novel therapies. Eur Heart J. 2022, ehac223. doi: 10.1093/eurheartj/ehac223.
Reboll MR, Klede S, Taft MH, …, Pich A, Bauersachs J, Wu X, Zheng L, Wang Y, Korf-Klingebiel M, Polten F, Wollert KC. Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science 2022;376(6599):1343-1347. doi: 10.1126/science.abn3027.
Chioncel O, Adamo M, Bauersachs J. Risk Stratification in Cardiogenic Shock: from clinical utility to improving outcomes. Eur J Heart Fail. 2022. doi: 10.1002/ejhf.2465.
Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022: 43:367-376. doi: 10.1093/eurheartj/ehab887
Szaroszyk M, Kattih B, …., Wollert KC, Fielitz J, von Haehling S, Kuhn M, Bauersachs J, Heineke J. Skeletal muscle derived Musclin protects the heart during pathological overload. Nature Communications 2022, 13:149. doi: 10.1038/s41467-021-27634-5
Bauersachs J, López-Andrés N. Mineralocorticoid receptor in cardiovascular diseases – Clinical trials and mechanistic insights. Br J Pharmacol. 2021 Oct 13. doi: 10.1111/bph.15708.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, …., Tribouilloy C, Wojakowski W. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021 doi: 10.1093/eurheartj/ehab395.
Fraccarollo D, Neuser J, Möller J, Riehle C, Galuppo P, Bauersachs J. Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. Elife. 2021; 10:e66808. doi: 10.7554/eLife.66808.
- Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, Bauersachs J. The struggle towards a Universal Definition of Heart Failure-how to proceed? Eur Heart J. 2021;42:2331-2343. doi: 10.1093/eurheartj/ ehab082
- Bauersachs J. Heart failure drug therapy – the fantastic four. Eur Heart J. 2021; 42:681-683. doi: 10.1093/eurheartj/ehaa1012.
Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, Schäfer A, Ross TL, Bauersachs J, Bengel FM. Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region After Acute Myocardial Infarction. J Am Coll Cardiol. 2021;77:1835-1837. doi: 10.1016/j.jacc.2021.02.019.
Bueno H, Moura B, Lancellotti P, Bauersachs J. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Eur Heart J. 2021 Jan 3:ehaa1061. doi: 10.1093/eurheartj/ehaa1061.
- Sliwa K, van der Meer P, Petrie MC, …, Lyon AR, Rosano G, Seferovic PM, Bauersachs J. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2021;23):527-540. doi: 10.1002/ejhf.2133.
Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, Thum T. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2020 Nov 11:ehaa898. doi: 10.1093/eurheartj/ehaa898.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, …., Rutten FH, Sibbing D, Siontis GCM. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020; doi: 10.1093/eurheartj/ehaa575.
Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, …., Ponikowski P, Van Veldhuisen DJ, McMurray J, Bauersachs J. On behalf of the EurObservational Research Programme in conjunction with the HFA of the ESC Study Group on Peripartum Cardiomyopathy. Clinical presentation, management and 6-month outcomes in women with peripartum cardiomyopathy, an ESC EORP registry. Eur Heart J 2020, in press.
Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020 doi: 10.1007/s00392-020-01636-7.
Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, …., Duncker D, Veltmann C, Hilfiker-Kleiner D, Bauersachs J. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail. 2019; 12:1534-1542. doi: 10.1002/ejhf.1624.
Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, …, Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the HFA of the ESC Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019. doi: 10.1002/ejhf.1493.
Malek Mohammadi M, Kattih B, Grund A, Froese N, Korf-Klingebiel M, Gigina A, Schrameck U, Rudat C, Liang Q, Kispert A, Wollert KC, Bauersachs J, Heineke J. The transcription factor GATA4 promotes myocardial regeneration in neonatal mice. EMBO Mol Med. 2019; 6. pii: e10678. doi: 10.15252/ emmm.201910678.
Bavendiek U, Berliner D, Aguirre Dávila L, …, v. d. Leyen H, Schröder C, Veltmann C, Störk S, Böhm M, Koch A, Bauersachs J. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail, 2019 21(5):676-684. doi: 10.1002/ejhf.1452.
Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res 2019;115(13):1838-1849. doi: 10.1093/cvr/cvz161.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, …, Swan L, Warnes CA. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018, 39: 3165-3241. doi: 10.1093/eurheartj/ehy340.
Koehler F, Koehler K, Deckwart O, … Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018 pii: S0140-6736(18)31880-4. doi: 10.1016/S0140-6736(18)31880-4.
Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, ….., Podewski E, Böhm M, Sliwa K, Bauersachs J (2017). Bromocriptine for the Treatment of Peripartum Cardiomyopathy: A Multicenter Randomized Study. Eur Heart J 38, 2671-2679. doi: 10.1093/eurheartj/ehx355.
Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C, ….. Dickstein K, Schultheiss HP, Ladage D, Greulich S, Bauersachs J (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J, doi: 10.1093/eurheartj/ehx188.
Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J (2017). Assumption versus evidence – the case of digoxin in atrial fibrillation and heart failure. Eur Heart J, pii: ehw577. doi: 10.1093/eurheartj/ehw577.
Bauersachs J, Arrigo M, Denise Hilfiker-Kleiner DF, ….., Seferovic P, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K (2016). Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 18, 1096-105.
Bauersachs J, Jaisser F, Toto R Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65, 257-263.
Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J, DOI: 10.1093/eurheartj/ehv009.
Zwadlo C, Schmidtmann E, Szaroszyk M, …, Hinz H, Schmitto JD, Widder J, Batkai S, Bähre H, Kaever V, Thum T, Bauersachs J, Heineke J (2015). Anti-androgenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. Circulation, 131:1071-1081.
Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J. (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408.
Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.
Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J (2011). Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 32, 1275-86.
Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 *joint senior authors.
Fraccarollo D, Widder JD, Galuppo P, Thum T, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008). Improvement of left ventricular remodelling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118, 818-82.
Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.
